MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations - Journal of Thoracic Oncology
Expanding treatment options in NSCLC patients with rare mutations: ALK, ROS1, MET, BRAF - memoinOncology
Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study | Journal of Translational Medicine | Full Text
Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing - Lung Cancer
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells | Oncogenesis
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
Crizotinib displays potent anti-tumour efficacy in an MET amplification... | Download Scientific Diagram
Effect of Crizotinib on c-MET expression in c-MET altered cancer cells.... | Download Scientific Diagram
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - Cancer Treatment Reviews
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Abstract - Europe PMC
Dramatic Response to Combination Erlotinib and Crizotinib in a Patient with Advanced, EGFR-Mutant Lung Cancer Harboring De Novo MET Amplification Justin. - ppt download
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
Chidamide increases the sensitivity of non-small cell lung cancer to crizotinib by decreasing c-MET mRNA methylation | bioRxiv
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration | Nature Medicine
MEK inhibitors against MET-amplified non-small cell lung cancer
Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib - Clinical Lung Cancer
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway - eBioMedicine
Safety and Tolerability of c-MET Inhibitors in Cancer | SpringerLink
Table 1 from Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib | Semantic Scholar
MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregula | OTT
MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations - ScienceDirect
Crizotinib in Patients With MET-Amplified NSCLC - Journal of Thoracic Oncology
